Apellis Pharmaceuticals (APLS) stock falls as company's Q3 2024 financials disappoint with lower-than-expected U.S. sales ...

In late-session trading, investors were selling out of Apellis, to the point where its price was down by nearly 6%. By ...

Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price target decreased by Bank of America from $61.00 to $47.00 ...

Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for ...

Apellis Pharmaceuticals, Inc. (NASDAQ:APLS – Free Report) – Research analysts at HC Wainwright reduced their FY2024 earnings ...

Apellis Pharmaceuticals, Inc. APLS incurred third-quarter 2024 loss of 46 cents per share, wider than the Zacks Consensus Estimate of a loss of 32 cents. The company had incurred a loss of $1.17 per ...

BofA lowered the firm’s price target on Apellis (APLS) to $47 from $61 and keeps a Buy rating on the shares after the company reported ...

Apellis Pharmaceuticals Inc (APLS) reports significant revenue growth but faces market and regulatory hurdles in Q3 2024.

In a report released today, Greg Harrison from Scotiabank maintained a Hold rating on Apellis Pharmaceuticals (APLS – Research Report), ...

Because this plan is a short plan based on a test of resistance it is referred to as a Short Resistance Plan. Check the time ...

Q3 2024 Earnings Call Transcript November 5, 2024 Apellis Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.46 EPS, expectations were $-0.32. Operator: Good morning, ladies ...